TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $70.58 million. The enterprise value is $35.06 million.
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 65.35 million shares outstanding. The number of shares has increased by 6.20% in one year.
| Current Share Class | 61.07M |
| Shares Outstanding | 65.35M |
| Shares Change (YoY) | +6.20% |
| Shares Change (QoQ) | +5.62% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 42.11% |
| Float | 55.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.73 |
| Forward PS | 10.78 |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.65, with a Debt / Equity ratio of 0.95.
| Current Ratio | 6.65 |
| Quick Ratio | 6.41 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -45.59 |
Financial Efficiency
Return on equity (ROE) is -80.95% and return on invested capital (ROIC) is -31.89%.
| Return on Equity (ROE) | -80.95% |
| Return on Assets (ROA) | -29.62% |
| Return on Invested Capital (ROIC) | -31.89% |
| Return on Capital Employed (ROCE) | -69.61% |
| Weighted Average Cost of Capital (WACC) | 5.71% |
| Revenue Per Employee | $64,338 |
| Profits Per Employee | -$875,387 |
| Employee Count | 142 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.52% in the last 52 weeks. The beta is 1.06, so TCRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | -25.52% |
| 50-Day Moving Average | 1.11 |
| 200-Day Moving Average | 1.33 |
| Relative Strength Index (RSI) | 47.31 |
| Average Volume (20 Days) | 669,675 |
Short Selling Information
The latest short interest is 870,161, so 1.33% of the outstanding shares have been sold short.
| Short Interest | 870,161 |
| Short Previous Month | 942,877 |
| Short % of Shares Out | 1.33% |
| Short % of Float | 1.57% |
| Short Ratio (days to cover) | 0.70 |
Income Statement
In the last 12 months, TCRX had revenue of $9.14 million and -$124.31 million in losses. Loss per share was -$2.07.
| Revenue | 9.14M |
| Gross Profit | -95.53M |
| Operating Income | -126.70M |
| Pretax Income | -124.31M |
| Net Income | -124.31M |
| EBITDA | -123.82M |
| EBIT | -126.70M |
| Loss Per Share | -$2.07 |
Full Income StatementBalance Sheet
The company has $128.06 million in cash and $92.54 million in debt, with a net cash position of $35.52 million or $0.54 per share.
| Cash & Cash Equivalents | 128.06M |
| Total Debt | 92.54M |
| Net Cash | 35.52M |
| Net Cash Per Share | $0.54 |
| Equity (Book Value) | 96.92M |
| Book Value Per Share | 1.61 |
| Working Capital | 112.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$122.01 million and capital expenditures -$2.95 million, giving a free cash flow of -$124.96 million.
| Operating Cash Flow | -122.01M |
| Capital Expenditures | -2.95M |
| Depreciation & Amortization | 2.88M |
| Net Borrowing | n/a |
| Free Cash Flow | -124.96M |
| FCF Per Share | -$1.91 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,386.84% |
| Pretax Margin | -1,360.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.20% |
| Shareholder Yield | -6.20% |
| Earnings Yield | -176.12% |
| FCF Yield | -177.05% |
Analyst Forecast
The average price target for TCRX is $6.00, which is 455.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 455.56% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 58.58% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TCRX has an Altman Z-Score of -4.59 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.59 |
| Piotroski F-Score | 3 |
